Related Experiment Video
Updated: Apr 12, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
Published on: November 7, 2017
Serum hepcidin predicts uremic accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy
Han Li, Su-Juan Feng, Lu-Lu Su
1Institute of Uro-Nephrology, Beijing Chao-Yang Hospital, Capital Medical University, Beijng 100020, China.
Insights
Elevated serum hepcidin levels are linked to accelerated atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. This suggests iron metabolism and hepcidin abnormalities may drive this condition.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Endocrinology
Background:
- Hepcidin regulates body iron stores and is implicated in anemia of chronic disease.
- Atherosclerotic cardiovascular disease is a major cause of mortality in chronic hemodialysis (CHD) patients.
- Diabetic nephropathy (DN) complicates CHD, increasing cardiovascular risk.
Purpose of the Study:
- To investigate the relationship between serum hepcidin and uremic accelerated atherosclerosis (UAAS) in CHD patients with DN.
- To compare hepcidin levels in CHD patients with and without DN.
Main Methods:
- Serum hepcidin-25 levels were measured using liquid chromatography-tandem mass spectrometry in 78 CHD/DN and 86 CHD/non-DN patients.
- Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels were quantified via ELISA.
- Common carotid artery intima media thickness (CCA-IMT) was assessed as a marker of atherosclerosis.
Main Results:
- Serum hepcidin-25 was significantly higher in CHD/DN patients compared to CHD/non-DN patients.
- Hepcidin-25 positively correlated with ferritin, hs-CRP, TNF-α, and IL-6 in CHD/DN patients.
- CCA-IMT, hs-CRP, and hepcidin-25 levels were elevated in CHD/DN patients; CCA-IMT correlated with hepcidin, hs-CRP, and LDL-C.
Conclusions:
- Findings suggest a link between iron metabolism, hepcidin dysregulation, and the development of UAAS in CHD/DN.
- Abnormalities in hepcidin may contribute to accelerated atherosclerosis in this patient population.
Background:
Hepcidin, as a regulator of body iron stores, has been recently discovered to play a critical role in the pathogenesis of anemia of chronic disease. Atherosclerotic cardiovascular disease is the most common complication and the leading cause of death in chronic hemodialysis (CHD) patients. In the current study, we aimed to explore the relationship between serum hepcidin and uremic accelerated atherosclerosis (UAAS) in CHD patients with diabetic nephropathy (CHD/DN).
Methods:
A total of 78 CHD/DN and 86 chronic hemodialyzed nondiabetic patients with chronic glomerulonephritis (CHD/non-DN) were recruited in this study. The level of serum hepcidin-25 was specifically measured by liquid chromatography-tandem mass spectrometry. Serum levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) were measured by enzyme-linked immunosorbent assay.
Results:
High serum level of hepcidin-25 was seen in CHD patients. Serum hepcidin-25 in CHD/DN was significantly higher than that in CHD/non-DN patients. Serum hepcidin-25 was positively correlated with ferritin, high-sensitivity C-reactive protein (hs-CRP), TNF-α, and IL-6 in CHD/DN patients. CHD/DN patients exhibited higher common carotid artery intima media thickness (CCA-IMT), hs-CRP, and hepcidin-25 levels than that in CHD/non-DN patients. Moreover, in CHD/DN patients, CCA-IMT was positively correlated with serum hepcidin, hs-CRP, and low-density lipoprotein-cholesterol. On multiple regression analysis, serum hepcidin and hs-CRP level exhibited independent association with IMT in CHD/DN patients.
Conclusions:
These findings suggest possible linkage between iron metabolism and hepcidin modulation abnormalities that may contribute to the development of UAAS in CHD/DN patients.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Hemodialysis II: Procedure and Complications
Hemodialysis I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic Kidney Disease I: Introduction

